Drugs / [18F]ASEM
[18F]ASEM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05462340 | Aug 2022 → Jan 2025 | schizophrenia | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04055467 | Dec 2019 → Oct 2022 | nicotine dependence | Johns Hopkins University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]ASEM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05462340 ↗ |
| Known as | 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide | “[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)” NCT04055467 ↗ |
| Known as | [F18]-ASEM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04055467 ↗ |
| Modality | Diagnostic / imaging agent | “PET radiopharmaceutical 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide” NCT04055467 ↗ |